Cargando…
Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy
Cancer immunotherapy has altered the management of human malignancies, improving outcomes in an expanding list of diseases. Breast cancer - presumably due to its perceived low immunogenicity - is a late addition to this list. Furthermore, most of the focus has been on the triple negative subtype bec...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2019
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562626/ https://www.ncbi.nlm.nih.gov/pubmed/31060337 http://dx.doi.org/10.3390/cancers11050628 |
_version_ | 1783426345239314432 |
---|---|
author | Chrétien, Sebastian Zerdes, Ioannis Bergh, Jonas Matikas, Alexios Foukakis, Theodoros |
author_facet | Chrétien, Sebastian Zerdes, Ioannis Bergh, Jonas Matikas, Alexios Foukakis, Theodoros |
author_sort | Chrétien, Sebastian |
collection | PubMed |
description | Cancer immunotherapy has altered the management of human malignancies, improving outcomes in an expanding list of diseases. Breast cancer - presumably due to its perceived low immunogenicity - is a late addition to this list. Furthermore, most of the focus has been on the triple negative subtype because of its higher tumor mutational load and lymphocyte-enriched stroma, although emerging data show promise on the other breast cancer subtypes as well. To this point the clinical use of immunotherapy is limited to the inhibition of two immune checkpoints, Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4). Consistent with the complexity of the regulation of the tumor – host interactions and their lack of reliance on a single regulatory pathway, combinatory approaches have shown improved efficacy albeit at the cost of increased toxicity. Beyond those two checkpoints though, a large number of co-stimulatory or co-inhibitory molecules play major roles on tumor evasion from immunosurveillance. These molecules likely represent future targets of immunotherapy provided that the promise shown in early data is translated into improved patient survival in randomized trials. The biological role, prognostic and predictive implications regarding breast cancer and early clinical efforts on exploiting these immune-related therapeutic targets are herein reviewed. |
format | Online Article Text |
id | pubmed-6562626 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2019 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-65626262019-06-17 Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy Chrétien, Sebastian Zerdes, Ioannis Bergh, Jonas Matikas, Alexios Foukakis, Theodoros Cancers (Basel) Review Cancer immunotherapy has altered the management of human malignancies, improving outcomes in an expanding list of diseases. Breast cancer - presumably due to its perceived low immunogenicity - is a late addition to this list. Furthermore, most of the focus has been on the triple negative subtype because of its higher tumor mutational load and lymphocyte-enriched stroma, although emerging data show promise on the other breast cancer subtypes as well. To this point the clinical use of immunotherapy is limited to the inhibition of two immune checkpoints, Programmed Cell Death Protein 1 (PD-1) and Cytotoxic T-lymphocyte-associated Protein 4 (CTLA-4). Consistent with the complexity of the regulation of the tumor – host interactions and their lack of reliance on a single regulatory pathway, combinatory approaches have shown improved efficacy albeit at the cost of increased toxicity. Beyond those two checkpoints though, a large number of co-stimulatory or co-inhibitory molecules play major roles on tumor evasion from immunosurveillance. These molecules likely represent future targets of immunotherapy provided that the promise shown in early data is translated into improved patient survival in randomized trials. The biological role, prognostic and predictive implications regarding breast cancer and early clinical efforts on exploiting these immune-related therapeutic targets are herein reviewed. MDPI 2019-05-05 /pmc/articles/PMC6562626/ /pubmed/31060337 http://dx.doi.org/10.3390/cancers11050628 Text en © 2019 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Chrétien, Sebastian Zerdes, Ioannis Bergh, Jonas Matikas, Alexios Foukakis, Theodoros Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy |
title | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy |
title_full | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy |
title_fullStr | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy |
title_full_unstemmed | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy |
title_short | Beyond PD-1/PD-L1 Inhibition: What the Future Holds for Breast Cancer Immunotherapy |
title_sort | beyond pd-1/pd-l1 inhibition: what the future holds for breast cancer immunotherapy |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6562626/ https://www.ncbi.nlm.nih.gov/pubmed/31060337 http://dx.doi.org/10.3390/cancers11050628 |
work_keys_str_mv | AT chretiensebastian beyondpd1pdl1inhibitionwhatthefutureholdsforbreastcancerimmunotherapy AT zerdesioannis beyondpd1pdl1inhibitionwhatthefutureholdsforbreastcancerimmunotherapy AT berghjonas beyondpd1pdl1inhibitionwhatthefutureholdsforbreastcancerimmunotherapy AT matikasalexios beyondpd1pdl1inhibitionwhatthefutureholdsforbreastcancerimmunotherapy AT foukakistheodoros beyondpd1pdl1inhibitionwhatthefutureholdsforbreastcancerimmunotherapy |